Plasmid DNA Manufacturing Market Size and Forecast — 2026-2033
Plasmid DNA Manufacturing Market is estimated to be valued at USD 1,660.1 Mn in 2026 and is expected to reach USD 6,951.1 Mn in 2033, exhibiting a compound annual growth rate (CAGR) of 22.7% from 2026 to 2033.
Plasmids are small circular molecules of DNA found in bacteria and other microscopic organisms. Plasmids are physically separated from the chromosomal DNA and replicate independently. They usually have a small number of genes, especially those associated with antibiotic resistance, that are passed from one cell to another. Plasmid DNA can be used directly as therapeutic agents, such as gene therapy and vaccine antigen generation, or indirectly for a variety of research applications such as the use of plasmid DNA as a key starting material for transient transfection.
Figure 1.Global Plasmid DNA Manufacturing Market Share (%), by Grade, 2026
Global Plasmid DNA Manufacturing Market - Driver
The increasing demand for plasmid (pDNA) DNA and increasing research and development activities by key players in the market is expected to drive the market growth over the forecast period. For instance, in October 2022, Forge Biologics, a contract development and manufacturing organization, announced the addition of plasmid DNA manufacturing to its Columbus, Ohio facility. The plasmid DNA manufacturing services encompass three grades which includes research grade, for discovery, research and development, etc.
Figure 2. Global Plasmid DNA Manufacturing Market Share (%), by Region, 2026
The increasing Inorganic strategies such as collaboration by key players in the market to expand product portfolio is expected to drive the market growth over the forecast period. For instance, in September 2022, Lonza, a global manufacturing partner to the pharma, biotech, and nutrition industries, announced its collaboration with Touchlight, a biotechnology company pioneering enzymatic DNA production, to enable the genetic medicine revolution. This collaboration will further help Lonza to integrate an additional, differentiated source of DNA in its end-to-end offering to customers developing messenger RNA therapeutics and vaccines.
Global Plasmid DNA Manufacturing Market: Key Developments
On October 10, 2022, Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for patients with retinal degenerative conditions, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced further collaboration for their manufacturing partnership to include clinical stage plasmid DNA production to support Ray Therapeutics’ lead optogenetics gene therapy program, RTx-015, in clinical trials for patients with retinitis Pigmentosa. By adding clinical grade plasmid production to their existing suite of associated viral vector (AAV) manufacturing capabilities, Forge is easing the scope of production and accelerating the development of lead therapeutic.
INOVIO plans to conduct the global INNOVATE Phase 3 segment in multiple countries, including Brazil, with partner Advaccine Biopharmaceuticals Suzhou Co., Ltd. (Advaccine).
- Current Industry Events of 2026
- Market Size Estimation
- Regional Breakdown
- Competitive Landscape
- Customer Intelligence
- Segmental Analysis
- Pricing Analysis
- Key Market Drivers, Challenges & Future Trends
- Customized Insights Section
Plasmid DNA Manufacturing Market Report Coverage
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,660.1 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 22.7% | 2033 Value Projection: | USD 6,951.1 Mn |
| Geographies covered: |
| ||
| Segments covered: |
| ||
| Companies covered: | Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing | ||
| Growth Drivers: |
| ||
| Restraints & Challenges: |
| ||
Global Plasmid DNA Manufacturing Market: Restraint
The high cost of gene therapies is adversely affecting the market growth. For instance, according to an article published by PubMed in May 2021, an upfront price of US$ 2.125 million, the one-time gene therapy onasemnogene abeparvovec for spinal muscular atrophy, a rare neuromuscular disorder that is usually fatal by 2 years of age if untreated, has been called the "most expensive drug ever”. Therefore, it is essential to lower the prices quoted by companies in order to increase the market reach.
Global Plasmid DNA Manufacturing Market: Key Players
Major players operating in the global plasmid DNA manufacturing market include Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing
Sources
Primary Research Interviews
- Plasmid DNA CDMOs (Aldevron/Danaher, Cobra Biologics/Charles River, VGXI, Thermo Fisher)
- Gene therapy and mRNA vaccine developers
- Bioprocess engineers specializing in plasmid production
Databases
- U.S. FDA Drug Master File data
Magazines
- BioProcess International
- GEN
Journals
- Molecular Therapy (Cell Press)
- Biotechnology and Bioengineering
Newspapers
- Reuters Health
Associations
- American Society of Gene & Cell Therapy (ASGCT)
- Alliance for Regenerative Medicine (ARM)
Public Domain Sources
- U.S. FDA – Cellular and Gene Therapy
Proprietary Elements
- CMI Data Analytics Tool, Proprietary CMI Existing Repository of information for last 10 years.
Get access to 250+ pages report
Every segment, forecast, competitor profile and data table behind the analysis above — available for instant download.
- ESOMAR Member
- ISO 9001:2015 Certified
- D-U-N-S Registered
- GDPR & CCPA Compliant
Missing comfort of reading report in your local language? Find your preferred language:
Transform your Strategy with Exclusive Trending Reports
Frequently Asked Questions
The Plasmid DNA Manufacturing Market is estimated to be valued at USD 1,660.1 Mn in 2026, and is expected to reach USD 6,951.1 Mn by 2033.
The CAGR of the Plasmid DNA Manufacturing Market is projected to be 22.7% from 2026 to 2033.
The increasing demand for plasmid (pDNA) DNA and increasing research and development activities by key players in the market and the increasing Inorganic strategies such as collaboration by key players in the market to expand product portfolio are expected to drive the global plasmid DNA manufacturing market growth.
Viral vectors is the leading product type segment in the market.
The major factors that can hamper growth of the market include the complex manufacturing process of plasmid DNA, the high cost of gene therapies
Major players operating in the market include Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing